Revlimid
(lenalidomide) Bristol Myers Squibb

Composition:
• Available in hard capsule with each contains 5 mg, 10 mg, 15 mg or 25 mg lenalidomide for oral administration

Indications:
• As monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation

• As combination therapy for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant

• In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.
The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.